Scientists have achieved a significant milestone in the field of oncology with the development of a groundbreaking test that allows for faster and earlier diagnosis of deadly ovarian cancers compared to current diagnostic methods.
Ovarian cancer, specifically epithelial ovarian cancer, is an exceptionally lethal form of cancer and accounts for 90% of all ovarian cancer cases. Unfortunately, individuals diagnosed with this type of cancer typically have a survival rate of only five years. The main reason behind such a low survival rate is the lack of noticeable symptoms, leading to late-stage detection.
Although the CA125 blood test, which measures a specific protein, is commonly used to detect ovarian cancer, it is not always reliable. For instance, a population screening program conducted on more than 200,000 women in the UK failed to reduce the number of deaths from ovarian cancer.
However, a team of researchers led by Pan Wang at Peking University in China has developed a new test that shows great promise. The researchers collected uterine fluid samples from 219 female cancer patients, including those with early-stage ovarian cancer, late-stage ovarian cancer, benign ovarian cancer, and endometrial cancer.
This fluid, originating from the ovaries and fallopian tubes, contains cells and metabolites, which are metabolic products. Through their analysis, the scientists discovered that the metabolites of 96 women exhibited distinct characteristics compared to those in the early stages of ovarian cancer.
The researchers identified a group of seven metabolites, including the amino acids tyrosine and phenylalanine, which could be utilized for the diagnosis of ovarian cancer. Furthermore, they conducted standard CA125 testing, commonly used for cancer detection, and concluded that the new test accurately diagnoses ovarian cancer in its early stages.
Eric Eisenhauer at Massachusetts General Hospital in Boston commented on the findings, stating, “The results are promising, but the test needs to be validated in a larger group of people.”
He further added, “Efficient non-surgical testing for early-stage ovarian cancer has been a challenge for over five decades. Although I would like to see this profile validated in a larger prospective data set, this initial report demonstrates significant promise.”
Despite the promising results, experts suggest that additional factors influencing cancer diagnosis at various stages should be taken into account. The study did not include a comparison group of individuals without cancer, and there may be other conditions that cause similar changes in metabolite profiles, as noted by Sujata Rawat at Adesh Hospital in Bathinda, India.
Published in PakWeb, June 13th, 2023.
Stay informed and engaged with the PakWeb by following us on Facebook, Twitter, and participating in our Discussion Forums.
